GLIXOV: GLIX5 for Ovarian Cancer

Cancer is the second-leading cause of death worldwide, representing a growing global health crisis and one of the most intractable diseases humanity has ever faced. For most cancers, only a small fraction of patients gets a meaningful benefit from current therapies, which means that most cancer-associated healthcare costs are “wasted” on ineffective treatments. Ovarian cancer (OC) remains essentially an incurable disease for which survival rates have only modestly improved, highlighting the urgent need to identify innovative strategies for its targeting. Hemispherian has identified a novel drug – GLIX5 – which targets a previously unknown DNA regulatory pathway with unprecedented anti-tumour efficacy. This drug has the potential to be co-developed with a sensitivity predictive biomarker (SPB), providing a one-of-a-kind patient-centric approach to devise effective and personalized treatment interventions. Importantly, GLIX5 has demonstrated preliminary strong efficacy against a broad range of different cancers, revealing its potential for widespread application in other indications with unmet need for effective therapies. In this project, we aim at advancing the preclinical development of GLIX5, while screening for other preferred indications for this treatment, through a SPB-driven approach. Our solution answers the urgent need for smarter interventions that translate into better coverage, more targeted healthcare, and lower spending on hospitalization or unnecessary treatments. Crucially, this solution brings a new therapeutic option that follows the vision for precision medicine in clinical practice and offers OC patients the chance for more moments that matter, with family and friends.

Cancer is the second-leading cause of death worldwide, representing a growing global health crisis and one of the most intractable diseases humanity has ever faced. For most cancers, only a small fraction of patients gets a meaningful benefit from current therapies, which means that most cancer-associated healthcare costs are “wasted” on ineffective treatments. Ovarian cancer (OC) remains essentially an incurable disease for which survival rates have only modestly improved, highlighting the urgent need to identify innovative strategies for its targeting. Hemispherian has identified a novel drug – GLIX5 – which targets a previously unknown DNA regulatory pathway with unprecedented anti-tumour efficacy. This drug has the potential to be co-developed with a sensitivity predictive biomarker (SPB), providing a one-of-a-kind patient-centric approach to devise effective and personalized treatment interventions. Importantly, GLIX5 has demonstrated preliminary strong efficacy against a broad range of different cancers, revealing its potential for widespread application in other indications with unmet need for effective therapies. In this project, we aim at advancing the preclinical development of GLIX5, while screening for other preferred indications for this treatment, through a SPB-driven approach. In addition, we will develop a new, scalable, and cost-efficient CMC process for GLIX5 synthesis and GMP production, which will precede pharmacological preclinical safety studies. Our solution answers the urgent need for smarter interventions that translate into better coverage, more targeted healthcare, and lower spending on hospitalization or unnecessary treatments. Crucially, this solution brings a new therapeutic option that follows the vision for precision medicine in clinical practice and offers OC patients the chance for more moments that matter, with family and friends.